Latest / Business Strategy Talks with Fexingo: Competitive Advantage, Market Positioning, and Growth Planning
How Novo Nordisk Built a Moat in Obesity Drugs
In this episode, Lucas and Luna break down how Novo Nordisk turned a diabetes drug into a blockbuster obesity franchise. They examine the GLP-1 market, the manufacturing bottleneck that has created a temporary monopoly, and the strategic bets on capacity that could define the company's next decade. Specific numbers: $2.5 billion in Wegovy sales in 2024, a 50 percent gross margin advantage over competitors, and a $6 billion manufacturing expansion in Denmark. Lucas argues that Novo's real moat isn't the patent — it's the production scale. Luna pushes back on the risk of…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.